Cargando…

Vascular density in age-related macular degeneration after one year of antiVEGF treatment with treat-and-extend and fixed regimens

Treatment of neovascular age-related macular degeneration (nAMD) with VEGF can be performed with several posologies. The purpose of our cross-sectional study was to analyze retinal vessel density by quantitative OCT-angiography (OCT-A) and to compare treat-and-extend (T&E) and fixed treatment pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Resch, Miklós D., Balogh, Anikó, Deák, Gábor Gy, Nagy, Zoltán Z., Papp, András
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7043775/ https://www.ncbi.nlm.nih.gov/pubmed/32101581 http://dx.doi.org/10.1371/journal.pone.0229388

Ejemplares similares

Subjective health expectations of patients with age-related macular degeneration treated with antiVEGF drugs
por: Péntek, Márta, et al.
Publicado: (2017)

Atrophy of retinal vessels in neovascular age-related macular degeneration following long-term treatment with 20 intravitreal anti-VEGF injections
por: Resch, Miklós D., et al.
Publicado: (2022)

Association between retinal vessel density and postoperative time after primary repair of rhegmatogenous retinal detachment
por: Resch, Miklós D., et al.
Publicado: (2021)

Intraocular neutralizing antibodies against aflibercept in patients with age related macular degeneration
por: Gyenes, Andrea, et al.
Publicado: (2023)

Seven-year outcomes following intensive anti-vascular endothelial growth factor therapy in patients with exudative age-related macular degeneration
por: Lukacs, Regina, et al.
Publicado: (2023)

A Systematic Review of the Treat and Extend Treatment Regimen with Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration
por: Gemenetzi, Maria, et al.
Publicado: (2017)

Cost-minimisation analysis of a treat-and-extend regimen with anti-VEGFs in patients with neovascular age-related macular degeneration
por: Quist, S. W., et al.
Publicado: (2021)

Outcome of 5-Year Treatment of Neovascular Age-Related Macular Degeneration With Intravitreal Anti-VEGF Using “Treat and Extend” Regimen
por: Jaki Mekjavic, Polona, et al.
Publicado: (2018)

Position of macula lutea and presence of proliferative vitreoretinopathy affect vitreous cytokine expression in rhegmatogenous retinal detachment
por: Balogh, Anikó, et al.
Publicado: (2020)

Reduced macular thickness and macular vessel density in early-treated adult patients with PKU
por: Serfozo, Csilla, et al.
Publicado: (2021)

Immunological biomarkers of the vitreous responsible for proliferative alteration in the different forms of retinal detachment
por: Balogh, Anikó, et al.
Publicado: (2020)

Anti-Vascular Endothelial Growth Factor Treatment for Macular Edema in Eyes with Branch Retinal Vein Occlusion with vs Without Glaucoma – Does Glaucoma Affect Visual Outcome in Eyes with BRVO-ME After antiVEGF Injections?
por: Asami, Shin, et al.
Publicado: (2022)

EXIT STRATEGY IN A TREAT-AND-EXTEND REGIMEN FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION
por: Arendt, Petra, et al.
Publicado: (2019)

Recurrence of neovascular age-related macular degeneration after cessation of treat and extend regimen
por: Hirata, Yuki, et al.
Publicado: (2022)

Visual Outcome and Treatment Frequency of Anti-VEGF Therapy Using the Treat-and-Extend and Treatment Cessation Regimen for Exudative Age-Related Macular Degeneration and Pachychoroid Neovasculopathy
por: Kinoshita, Takamasa, et al.
Publicado: (2021)

Continued anti-VEGF treatment does not prevent recurrences in eyes with stable neovascular age-related macular degeneration using a treat-and-extend regimen: a retrospective case series
por: Garweg, Justus G., et al.
Publicado: (2021)

Altered visual functions, macular ganglion cell and papillary retinal nerve fiber layer thickness in early-treated adult PKU patients
por: Serfozo, Csilla, et al.
Publicado: (2020)

Aflibercept for age-related macular degeneration: 4-year outcomes of a ‘treat-and-extend’ regimen with exit-strategy
por: Jaggi, Damian, et al.
Publicado: (2022)

Exploring the role of VEGF in Indian Age related macular degeneration
por: Sharma, Kaushal, et al.
Publicado: (2015)

Changes in metamorphopsia after the treat-and-extend regimen of anti-VEGF therapy for macular edema associated with branch retinal vein occlusion
por: Mori, Kenichiro, et al.
Publicado: (2020)

Segmentation of macular neovascularization and leakage in fluorescein angiography images in neovascular age-related macular degeneration using deep learning
por: Holomcik, David, et al.
Publicado: (2022)

Intravitreal aflibercept following treat and extend protocol versus fixed protocol for treatment of neovascular age-related macular degeneration
por: Abdin, Alaa Din, et al.
Publicado: (2021)

Optimal approaches and criteria to treat-and-extend regimen implementation for Neovascular age-related macular degeneration: experts consensus in Taiwan
por: Cheng, Cheng-Kuo, et al.
Publicado: (2022)

Patient satisfaction following a switch from treat-and-extend to observe-and-plan regimen in age-related macular degeneration
por: Morken, Tora Sund, et al.
Publicado: (2022)

One-year results of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization
por: Matsumoto, Hidetaka, et al.
Publicado: (2022)

Two-year outcomes of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization
por: Matsumoto, Hidetaka, et al.
Publicado: (2023)

New Approach of Anti-VEGF Agents for Age-Related Macular Degeneration
por: Park, Young Gun, et al.
Publicado: (2012)

Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration
por: García-Quintanilla, Laura, et al.
Publicado: (2019)

Application and mechanism of anti-VEGF drugs in age-related macular degeneration
por: Song, Dawei, et al.
Publicado: (2022)

Genetic biomarkers in the VEGF pathway predicting response to anti-VEGF therapy in age-related macular degeneration
por: Balikova, Irina, et al.
Publicado: (2019)

Pro re nata versus fixed aflibercept regimen for neovascular age-related macular degeneration: a systematic review and meta-analysis
por: Victor, Andi Arus, et al.
Publicado: (2022)

Physician, patient, and caregiver experience of different wet age-related macular degeneration anti-VEGF treatment regimens in Japan: a qualitative assessment
por: Iida, Tomohiro, et al.
Publicado: (2016)

Long-term Outcomes of Treat and Extend Regimen of Anti-vascular Endothelial Growth Factor in Neovascular Age-related Macular Degeneration
por: Lee, Andy, et al.
Publicado: (2020)

Quantitative Optical Coherence Tomography Angiography Biomarkers in a Treat-and-Extend Dosing Regimen in Neovascular Age-Related Macular Degeneration
por: Cabral, Diogo, et al.
Publicado: (2020)

A Randomized, Controlled Trial of Treat-and-Extend vs. Pro Re Nata Regimen for Neovascular Age-Related Macular Degeneration
por: Jia, Huixun, et al.
Publicado: (2022)

Disease stability and extended dosing under anti-VEGF treatment of exudative age-related macular degeneration (AMD) — a meta-analysis
por: Garweg, Justus G., et al.
Publicado: (2021)

VEGFA Haplotype and VEGF-A and VEGF-R2 Protein Associations with Exudative Age-Related Macular Degeneration
por: Vilkeviciute, Alvita, et al.
Publicado: (2022)

The effect of image quality on the reliability of OCT angiography measurements in patients with diabetes
por: Czakó, Cecília, et al.
Publicado: (2019)

Psychological impact of anti-VEGF treatments for wet macular degeneration—a review
por: Senra, Hugo, et al.
Publicado: (2016)

Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration
por: Kaiser, Stephanie M, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8mr075qu0gaoj6ept7qbhog4rk